Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC-201 in Moderate to Severe Plaque Psoriasis
CTR20240483Phase 2Completed
- Sponsor
- Akno Biopharmaceutical
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in psoriasis comparing AC-201 tablets with Placebo tablets (2 arms). Primary endpoint: PASI75 response at Week 12. Started Feb 2024; status: completed.
02
Drugs
AC-201CR
03
Conditions
psoriasis
Beyond the preview
Go deeper on CTR20240483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240483.